- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02956044
Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin
A Phase 1, Open-label, Randomized, Three-period, Crossover Study to Evaluate Pharmacokinetic Interaction Between Bexagliflozin Tablets and Metformin, Glimepiride, or Sitagliptin in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A total of 54 healthy subjects were enrolled and assigned to one of three groups of eighteen. Each group participated in one of three open-label, randomized, three treatment period, crossover studies:
- Group 1: Bexagliflozin/metformin drug-drug interaction (DDI)
- Group 2: Bexagliflozin/glimepiride DDI
- Group 3: Bexagliflozin/sitagliptin DDI For each Group, every subject received a single dose of bexagliflozin tablet, 20 mg, alone, a single dose of an oral hypoglycemic agent (OHA) (1000 mg metformin, 2 mg glimepiride, or 100 mg sitagliptin) alone, and the combination of both (bexagliflozin tablet and OHA) alternately in a crossover fashion, with three treatment periods separated by a washout period of at least 7 days. Within each Group, subjects were randomized to one of six treatment sequences in an equal ratio.
To prevent hypoglycemia, subjects assigned to Group 2 (bexagliflozin/glimepiride DDI) received approximately 300 mL of a solution containing 50 g of glucose with study medication at the time of dosing, as well as approximately 75 mL of a solution containing 12.5 g of glucose every 15 minutes for 4 hours post-dose.
For each treatment period in Group 1 (bexagliflozin/metformin DDI) and Group 2 (bexagliflozin/glimepiride DDI), subjects were admitted to the clinic on the day before dosing and stayed in the clinic until 48 h post-dose. For Group 3 (bexagliflozin/sitagliptin DDI), subjects stayed in the clinic until 72 h post-dose.
For all Groups, blood samples for PK analysis were collected in each period prior to dosing (pre-dose) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose. For Group 3, PK blood samples were also collected at 60 and 72 h post-dose. Plasma concentrations of bexagliflozin and OHAs were determined by validated liquid chromatography tandem mass spectrometry (LC MS/MS) assays.
Urine samples for PD analysis were collected in 12 h intervals. For all Groups, urine samples were collected pre-dose (-12 to 0 h) and post-dose at 0 to 12 h, 12 to 24 h, 24 to 36 h, and 36 to 48 h. For Group 3, additional samples at 48 to 60 h and 60 to 72 h post-dose were collected.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Indiana
-
Evansville, Indiana, United States, 47710
- Clinical Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2
- Subjects who are non-smokers for at least 3 months prior to screening
- Subjects who are willing and able to be confined to the clinical research facility as required by the protocol
Exclusion Criteria:
- Subjects with a clinically significant history of allergy to drugs or latex.
- Subjects with a history of alcohol or drug dependence in the past 12 months.
- Subjects who have donated a significant amount of blood in the past 2 months
- Female subjects who are pregnant or breastfeeding
- Subjects who are not willing to use an adequate form of birth control during the study and for 30 days after discharge from clinic
- Subjects who have taken an investigational drug in the past 30 days or 7 half-lives of the investigational drug, whichever is longer
- Subjects who had previously received anti-diabetic medication, including metformin, sitagliptin, glimepiride or drugs of the same class (i.e. biguanides, DPP-4 inhibitors or sulfonylureas), or SGLT2 inhibitors, in the past 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group 1: Bexagliflozin alone
|
Bexagliflozin tablets, 20 mg
|
Active Comparator: Group 1: Metformin alone
|
1000 mg metformin
|
Active Comparator: Group 1: Bexagliflozin + Metformin
|
Bexagliflozin tablets, 20 mg
1000 mg metformin
|
Active Comparator: Group 2: Bexagliflozin alone
|
Bexagliflozin tablets, 20 mg
|
Active Comparator: Group 2: Glimepiride alone
|
4 mg glimepiride
|
Active Comparator: Group 2: Bexagliflozin + Glimepiride
|
Bexagliflozin tablets, 20 mg
4 mg glimepiride
|
Active Comparator: Group 3: Bexagliflozin alone
|
Bexagliflozin tablets, 20 mg
|
Active Comparator: Group 3: Sitagliptin alone
|
100 mg sitagliptin
|
Active Comparator: Group 3: Bexagliflozin + Sitagliptin
|
100 mg sitagliptin
Bexagliflozin tablets, 20 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax (Maximum Observed Plasma Concentration)
Time Frame: Up to 72 hours
|
Whole venous blood samples of 5 mL were be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. Pharmacokinetic (PK) blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed.
Cmax was obtained directly from experimental observations.
|
Up to 72 hours
|
Tmax (Time of Maximum Observed Plasma Concentration)
Time Frame: Up to 72 hours
|
Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed.
Tmax was obtained directly from experimental observations.
|
Up to 72 hours
|
T1/2 (Apparent Terminal Elimination Half-life)
Time Frame: Up to 72 hours
|
Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed.
T1/2 was obtained directly from experimental observations.
|
Up to 72 hours
|
AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)
Time Frame: Up to 72 hours
|
Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed.
AUC0-inf was estimated for each subject.
|
Up to 72 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urinary Glucose Excretion up to 0-72 hr
Time Frame: up to 0-72 hr
|
Pre-dose urine samples were collected from -12 to 0 h for baseline measurement.
Subjects was instructed to empty their bladder prior to dosing.
Post-dose urine was collected in 4 batches for Groups 1 and 2 at 0 to 12 h, 12 to 24 h, 24 o 36 h, and 36 to 48 h collections.
Post-dose urine was collected in batches for Group 3 at 0 to 12 h, 12 to 24 h, 24 to 36 h, 36 to 48 h, 48 to 60 h and 60 to 72 h.
|
up to 0-72 hr
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Mason Freeman, M.D., Massachusetts General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Enzyme Inhibitors
- Immunosuppressive Agents
- Immunologic Factors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Incretins
- Dipeptidyl-Peptidase IV Inhibitors
- Metformin
- Sitagliptin Phosphate
- Glimepiride
- Bexagliflozin
Other Study ID Numbers
- THR-1442-C-453
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type2 Diabetes Mellitus
-
Mathias Ried-LarsenUnknownDiabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus | Type2 Diabetes | Type2 Diabetes MellitusDenmark
-
Sigrid Therapeutics ABCompletedOverweight | PreDiabetes | Prediabetic State | Type2 Diabetes | Obese | Type2 Diabetes Mellitus | Pre DiabetesFinland, Sweden
-
Hamad Medical CorporationQatar Computing Research Institute (QCRI); Droobi HealthUnknown
-
Andalas UniversityUniversiti Putra MalaysiaCompleted
-
Medstar Health Research InstituteCompletedType2 Diabetes Mellitus
-
Boryung Pharmaceutical Co., LtdRecruiting
-
Georgia Institute of TechnologyNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Emory...CompletedType2 Diabetes MellitusUnited States
-
EMSWithdrawnType2 Diabetes Mellitus
-
Chong Kun Dang PharmaceuticalUnknown
-
Chong Kun Dang PharmaceuticalUnknownType2 Diabetes MellitusKorea, Republic of
Clinical Trials on Sitagliptin
-
Merck Sharp & Dohme LLCCompleted
-
Emory UniversityMerck Sharp & Dohme LLCTerminated
-
Baylor College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedType 1 DiabetesUnited States
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedType 2 Diabetes MellitusChina
-
University of Colorado, DenverMerck Sharp & Dohme LLCCompletedCardiovascular Disease | Type 2 DiabetesUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
University Hospital Inselspital, BerneFresenius KabiCompletedMalnourishment | Gastrointestinal TumorsSwitzerland
-
Second Affiliated Hospital of Soochow UniversityUnknown
-
Beijing Chao Yang HospitalRecruiting